JP2017524007A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524007A5
JP2017524007A5 JP2017507009A JP2017507009A JP2017524007A5 JP 2017524007 A5 JP2017524007 A5 JP 2017524007A5 JP 2017507009 A JP2017507009 A JP 2017507009A JP 2017507009 A JP2017507009 A JP 2017507009A JP 2017524007 A5 JP2017524007 A5 JP 2017524007A5
Authority
JP
Japan
Prior art keywords
methyl
cis
pyrrolo
cyclobutyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017507009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524007A (ja
JP6585158B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/055823 external-priority patent/WO2016024185A1/en
Publication of JP2017524007A publication Critical patent/JP2017524007A/ja
Publication of JP2017524007A5 publication Critical patent/JP2017524007A5/ja
Application granted granted Critical
Publication of JP6585158B2 publication Critical patent/JP6585158B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017507009A 2014-08-12 2015-07-31 ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体 Expired - Fee Related JP6585158B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462036276P 2014-08-12 2014-08-12
US62/036,276 2014-08-12
US201562189347P 2015-07-07 2015-07-07
US62/189,347 2015-07-07
PCT/IB2015/055823 WO2016024185A1 (en) 2014-08-12 2015-07-31 Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase

Publications (3)

Publication Number Publication Date
JP2017524007A JP2017524007A (ja) 2017-08-24
JP2017524007A5 true JP2017524007A5 (enExample) 2018-07-19
JP6585158B2 JP6585158B2 (ja) 2019-10-02

Family

ID=54148574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507009A Expired - Fee Related JP6585158B2 (ja) 2014-08-12 2015-07-31 ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体

Country Status (8)

Country Link
US (1) US10966980B2 (enExample)
EP (1) EP3180344B1 (enExample)
JP (1) JP6585158B2 (enExample)
CA (1) CA2899888A1 (enExample)
ES (1) ES2750655T3 (enExample)
TW (1) TW201619159A (enExample)
UY (1) UY36265A (enExample)
WO (1) WO2016024185A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
AU2021281643B2 (en) * 2014-02-11 2024-02-15 Pfizer Inc. Pyrrolo(2,3-d)pyrimidine derivatives
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
EP3512519A1 (en) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Syk inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
WO2018095320A1 (zh) * 2016-11-23 2018-05-31 江苏恒瑞医药股份有限公司 吡咯并六元杂芳环类衍生物的制备方法及中间体
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US12274703B2 (en) * 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
WO2019182924A1 (en) * 2018-03-21 2019-09-26 Xibin Liao Jak inhibitors
EP3817810B1 (en) 2018-07-06 2025-09-17 Pfizer Inc. Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
JP2022506682A (ja) * 2018-11-05 2022-01-17 アビスタ ファーマ ソリューションズ,インコーポレーテッド 化合物
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Prmt5を標的にする化合物
EP3969458A4 (en) 2019-05-13 2023-05-17 Borah, Inc. CHEMICAL COMPOUNDS
CN110483338A (zh) * 2019-08-14 2019-11-22 苏州汉德创宏生化科技有限公司 一种大环类抑制剂中间体环庚烷基磺酰氯的合成方法
EP4210828A1 (en) 2020-09-11 2023-07-19 Galderma Holding SA Novel jak inhibitor compounds, method for synthesizing same and use thereof
CN112697912B (zh) * 2020-12-14 2021-09-21 上海博悦生物科技有限公司 一种检测枸橼酸托法替布中间体及其相关杂质的方法
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
CA3251360A1 (en) 2022-02-14 2023-08-17 Arase Therapeutics Inc. PARG INHIBITORS
WO2024173234A1 (en) * 2023-02-13 2024-08-22 Arase Therapeutics Inc. Inhibitors of parg

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
BR9307646A (pt) 1992-12-17 1999-05-25 Pfizer Pirrolopirimidinas como antagonistas de crf
JPH06329675A (ja) 1993-05-20 1994-11-29 Teijin Ltd 4―置換アルキルアミノ―ピロロ[2,3―d]ピリミジン誘導体
JPH06329674A (ja) 1993-05-20 1994-11-29 Teijin Ltd 4―置換シクロヘキシルアミノ―ピロロ[2,3―d]ピリミジン
JPH08134068A (ja) 1994-11-02 1996-05-28 Teijin Ltd 4―置換アルキルアミノ―ピロロ[2,3―d]ピリミジン誘導体
US6051578A (en) 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
JP2002543200A (ja) 1999-04-30 2002-12-17 ニューロゲン コーポレイション 9H−ピリミド[4、5−b]インドール誘導体:CRF1特異性リガンド
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
OA12292A (en) 2000-06-26 2003-11-11 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents.
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
JP2005529062A (ja) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンa1及びa3受容体に特異的な化合物とその使用
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003299901A1 (en) 2002-10-04 2004-05-04 Merck And Co., Inc. Thrombin inhibitors
RS20050380A (sr) 2002-11-21 2007-11-15 Pfizer Products Inc., Derivati 3-aminopiperidina i postupci njihove proizvodnje
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2007012953A2 (en) 2005-07-29 2007-02-01 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
US20100273776A1 (en) 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
WO2009062118A2 (en) 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009060278A1 (en) 2007-11-08 2009-05-14 Pfizer Inc. Cyclobutyl carboxylic acid derivatives
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
RS53382B (sr) 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina
KR20110044304A (ko) 2008-09-18 2011-04-28 화이자 리미티드 치료에 유용한 아마이드 화합물
FR2948066B1 (fr) 2009-07-17 2012-01-20 Skf Ab Dispositif de butee de suspension et jambe de force.
AU2010308028A1 (en) 2009-10-15 2012-04-19 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
EP4782062A2 (en) 2009-12-01 2026-07-29 AbbVie Inc. Novel tricyclic compounds
CA2782720A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
CN102712640A (zh) 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
WO2011104652A2 (en) 2010-02-24 2011-09-01 Pfizer Inc. Veterinary compositions
CN103097340B (zh) 2010-07-16 2018-03-16 安吉奥斯医药品有限公司 治疗活性组合物及其使用方法
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
CN103391939B (zh) 2010-12-03 2016-03-09 Epizyme股份有限公司 作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
CA2833507A1 (en) 2011-06-07 2012-12-13 Dainippon Sumitomo Pharma Co., Ltd. Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
WO2014011911A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
PT2874630T (pt) 2012-07-20 2019-01-31 Zoetis Services Llc Regime de dosagem para inibidores de janus quinase (jak)
JP2014133739A (ja) 2012-12-12 2014-07-24 Dainippon Sumitomo Pharma Co Ltd インダゾール誘導体またはピロロピリジン誘導体からなる医薬
EA027879B1 (ru) * 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase

Similar Documents

Publication Publication Date Title
RU2484091C2 (ru) Производные изоксазоло-пиридина
AU2023356610A1 (en) Tethered heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
JP6655052B2 (ja) ビヘテロアリール化合物及びその使用
JP2019530739A5 (enExample)
JP5914667B2 (ja) ピロロピリミジンおよびプリン誘導体
KR101812357B1 (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
CN118974055A (zh) 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途
JP2018514560A5 (enExample)
RU2016124178A (ru) Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
JP6585158B2 (ja) ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP2019535664A5 (enExample)
JP2015522002A5 (enExample)
HRP20171913T1 (hr) Aminopirimidinilni spojevi kao inhibitori jak
JP2019523233A5 (enExample)
JP2018532760A5 (enExample)
JP2021504380A5 (enExample)
RU2013126657A (ru) Ингибиторы nampt и rock
JP2017505327A5 (enExample)
AU2016333721A1 (en) Spiro(3H-indole-3,2´-pyrrolidin)-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors
RU2018142987A (ru) Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m4
JP2014506929A5 (enExample)
RU2016135637A (ru) 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение
CA2873097A1 (en) Pyridazine and pyridine derivatives as nampt inhibitors
JP2015537010A5 (enExample)